ATLANTA--(BUSINESS WIRE)--March 13, 2006--Amgen's Phase 3 RED-HF(TM) Trial Will Evaluate the Clinical Effect of Treating Anemia in Patients with Symptomatic Heart Failure. Amgen (Nasdaq:AMGN), the world's largest biotechnology company, announced results from a Phase 2 study that showed that treating anemia with Aranesp(R) (darbepoetin alfa) in patients with symptomatic heart failure was well-tolerated, effectively raised hemoglobin and improved patients' symptoms as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). The results were presented today at the 2006 American College of Cardiology (ACC) Scientific Session.
